A Study on Changes in Nasal Polyps and Olfactory Dysfunction Treated with Dupilumab in 7 Cases of Chronic Rhinosinusitis with Nasal Polyps
Dupilumab is a humanized anti-human IL-4/13 receptor monoclonal antibody that has been approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), bronchial asthma, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria that respond insufficiently to existing treatments. Some patients with CRSwNP experience repeated relapses while receiving existing treatments, and for such cases, treatment with dupilumab is promising.
Authors
- Kei Shatari
- Shunichi Sasaki
- Kento Yumita
- Jun Morikawa
Institutions
- Ashikaga Red Cross Hospital (JP)
- National Defense Medical College (JP)
Publication Details
- Journal
- Practica Oto-Rhino-Laryngologica
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5631/jibirin.118.287
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00